MedTrace Logo

Bevacizumab for Central Retinal Vein Occlusion Study

NCT00906685 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2011-11-22

No results posted yet for this study

Summary

Central retinal vein occlusion is a leading cause of severe visual impairment. Until now, no treatment has been available to improve visual acuity. The present study intends to investigate if intravitreal bevacizumab can improve visual acuity as compared to sham-treated control patients.

Conditions

  • Central Retinal Vein Occlusion

Interventions

DRUG

bevacizumab

Intravitreal injection of 1.25 mg bevacizumab

DRUG

Sham bevacizumab injection

Sham intravitreal injection

Sponsors & Collaborators

  • Anders Kvanta

    lead OTHER

Principal Investigators

  • Anders Kvanta, MD, PhD · St Eriks Eye Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2011-03-31
Completion
2011-09-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00906685 on ClinicalTrials.gov